Chris Hill
@dochill82
Followers
260
Following
1K
Statuses
1K
Dad, kidney doc, Liverpool FC fan, cricket follower and TMS fanatic. #YNWA
Joined September 2015
The Simpsons on PhD students - almost twenty years old & more cutting than ever
1
0
2
RT @CritCareReviews: PARAMEDIC3 & IVIO trials presented at #RESUS24 & published in @NEJM IV vs IO access in out-of-hospital cardiac arrest…
0
6
0
RT @JASN_News: B-cell activating factor and A proliferation-inducing ligand play key roles in the pathogenesis of IgA nephropathy. This stu…
0
11
0
RT @NEJM: Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN)
0
42
0
RT @MichaelToal6: How do patients experience a kidney biopsy? Our paper explores how to facilitate access to this essential investigation.…
0
8
0
10 years as a consultant in the NHS today… Where did that decade go?
1
0
12
RT @edgarvlermamd: The Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV) from @goKDIGO is…
0
43
0
RT @Kidney_Int: A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtrati…
0
19
0
Encouraging results - a drug that may be able to stop chronic AMR in its tracks… The 1 year eGFR slopes look very encouraging but why no improvement in proteinuria?
Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: Editorial: Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last? #Nephrology
0
0
0
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)
0
44
0
RT @edgarvlermamd: RaDaR: In this IgA Nephropathy #IgAN cohort, patients traditionally regarded as being low risk, with proteinuria <0.88 g…
0
24
0
Registration is now open for the @RenalSpRClub Autumn Meeting 📣 🗣️ Transformative #Nephrology: Developing Skills Beyond the Clinic 🗓️ 21-22 September 2024 📍 Engineers House, Bristol Book your space now: 🎟️
1
0
1
RT @kidney_boy: COVID vaccines are associated with lower risk of death and hospitalization following covid infection. Three doses are bette…
0
3
0
Most convincing evidence yet for making GLP-1RA combined with SGLT2i standard of care in Type 2 DM. Saves kidneys, hearts and lives!
Our #SMARTC collaborative meta-analysis is now in @TheLancetEndo: Data from >73,000 people across 12 trials provides the strongest evidence yet for combined use of SGLT2i & GLP-1RA to improve clinical outcomes in diabetes Download free for 50 days here:
0
0
1
RT @brendonneuen: Our #SMARTC collaborative meta-analysis is now in @TheLancetEndo: Data from >73,000 people across 12 trials provides the…
0
44
0
RT @MichaelToal6: Busy week ahead presenting our results at #UKKW2024 & #INS24 . Manuscript almost ready for submission too. Thanks all wh…
0
5
0
RT @Kidney_Int: A Phase II randomized controlled trial evaluated antithrombotic treatment with #fesomersen in patients with #kidneyfailure…
0
4
0
RT @AJKDonline: Kidney Dysfunction in the Setting of Liver Failure: Core Curriculum 2024 (FREE) @SwethaKanduriMD…
0
75
0